Filing summary
Entity and period: The supplied filing is GlycoMimetics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015, not a filing identified in its text as Crescent Biopharma, Inc. The company is a clinical-stage biotechnology developer and had no commercialized products.
Financial performance
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $5.21 million | $3.88 million |
| General and administrative expense | $1.90 million | $1.22 million |
| Total costs and expenses | $7.11 million | $5.11 million |
| Net loss | $7.11 million | $5.10 million |
| Net loss per share, basic and diluted | $0.37 | $0.30 |
| Operating cash flow | $(8.71) million | $(2.59) million |
Revenue and gross margin are not applicable because the company reported no revenue. Expenses rose about 39% year over year; R&D increased 34%, chiefly from GMI-1271 manufacturing and process development, while G&A increased 56%, principally from public-company costs, professional fees, and stock compensation.
Financial position and liquidity
- Cash and cash equivalents were $46.57 million at March 31, 2015, down from $55.20 million at December 31, 2014. Total assets were $48.46 million; current liabilities were $4.10 million, with no long-term liabilities reported.
- Cash used in operations was $8.71 million; investing cash use was $2,339. Financing provided $75,377, primarily from stock-option exercises. The prior-year quarter included $57.26 million of IPO proceeds.
- The company reported no debt on its balance sheet and no off-balance-sheet arrangements. Management believed existing cash would fund operations and capital expenditures for at least 12 months from March 31, 2015, excluding potential Pfizer milestone payments.
- Operating cash use included payment of a $1.5 million accrued fee to the University of Basel, equal to 10% of Pfizer’s 2014 milestone payment.
Business, outlook, and risks
- Rivipansel is licensed to Pfizer, which is responsible for further development and commercialization. Pfizer had delayed its Phase 3 start over a manufacturing supply issue; in April 2015, it advised that it expected enrollment to begin in mid-2015, subject to FDA review of amended submissions. The first Phase 3 patient dosing would trigger a remaining $20 million milestone to GlycoMimetics.
- GMI-1271 is being developed for AML and other hematologic cancers. The company expected first enrollment in a Phase 1/2 AML trial in Q2 2015. A separate University of Michigan Phase 1 study evaluating GMI-1271 as an anticoagulant had begun dosing healthy volunteers in December 2014.
- Management expected R&D and G&A expenses to rise as clinical programs advance and public-company operations continue. The company warned that additional financing may be needed; access to capital is not assured, and equity financing could dilute shareholders.
- Major uncertainties include clinical-trial enrollment and results, regulatory approval, manufacturing, intellectual-property protection, and the timing or availability of Pfizer milestones. The company reported no material legal proceedings and said its risk factors had not materially changed from its 2014 annual report.
- The company had committed to lease 33,843 square feet of future office and laboratory space for an eight-year term beginning November 1, 2015, at annual base rent of $607,500, subject to escalations.
Most important facts to verify
- Confirm the intended issuer: the filing text identifies GlycoMimetics, Inc., while the request metadata names Crescent Biopharma, Inc.
- Check the actual timing and status of the Pfizer-funded rivipansel Phase 3 trial and whether the $20 million milestone was triggered.
- Assess cash runway against subsequent operating burn, trial costs, and the company’s stated financing needs.
- Review GMI-1271 trial progress and manufacturing readiness, and the terms and obligations of the future headquarters lease.